康臣药业11月7日斥资749.28万港元回购50.5万股

Core Viewpoint - 康臣药业 announced a share buyback plan, indicating confidence in its stock value and potential for future growth [1] Group 1 - 康臣药业 plans to repurchase 505,000 shares at a total cost of HKD 7.4928 million [1] - The buyback is scheduled for November 7, 2025, reflecting the company's strategic approach to enhance shareholder value [1]